Portage Biotech (NASDAQ:PRTG) Stock Price Up 0.3% – What’s Next?

Portage Biotech Inc. (NASDAQ:PRTG) shot up 0.3% during trading on Thursday . The stock traded as high as $4.13 and last traded at $3.82. 6,466 shares traded hands during trading, a decline of 99% from the average session volume of 495,940 shares. The stock had previously closed at $3.81.

Portage Biotech Stock Down 21.5 %

The company’s 50-day moving average is $5.07 and its two-hundred day moving average is $4.73. The company has a market capitalization of $3.15 million, a P/E ratio of -0.07 and a beta of 1.45.

Hedge Funds Weigh In On Portage Biotech

An institutional investor recently bought a new position in Portage Biotech stock. Virtu Financial LLC purchased a new stake in shares of Portage Biotech Inc. (NASDAQ:PRTG) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 10,919 shares of the company’s stock, valued at approximately $73,000. Virtu Financial LLC owned approximately 1.04% of Portage Biotech as of its most recent SEC filing. 13.36% of the stock is currently owned by institutional investors and hedge funds.

Portage Biotech Company Profile

Portage Biotech Inc, a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials.